CPhI and CPhI Pharma Evolution Announce Expert Industry Panel - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI and CPhI Pharma Evolution Announce Expert Industry Panel
13 full members with expertise across the entire pharmaceutical supply chain.


CPhI Worldwide, organized by UBM Live, and CPhI Pharma Evolution have announced its full expert industry panel list ahead of the publication of a forward looking annual report, due in September, which will examine future contingencies for the pharmaceutical industry. Members of the panel will take part in CPhI short monthly reports, entitled ‘CPhI Pharma Insight Series,’ which will examine topical issues across eight themes—Drug Delivery; Formulation & Ingredients; R&D; Manufacturing; Packaging & Distribution; Regulatory Compliance; Contract Services & Supply Chain Management; and QA/QC.

The panel has contributed to the first CPhI Pharma Evolution monthly report examining current trends in ‘formulation and ingredients’ including issues related to market growth, development of tablets, QbD, PAT, bioavailability, dissolution, stability and outsourcing.

Panel members have been chosen following an exhaustive selection process involving industry peers and journalists to ensure that they have the appropriate expertise to independently and holistically examine global trends. There are currently 13 experts in total, covering the entire sphere of the pharmaceutical supply chain, from R&D through to finished products, regulatory requirements and economic implications.

The aim is to utilize each member’s expertise to scrutinize how the industry will change in the coming five to ten years in an annual report. The report will feature a mixture of primary industry data (i.e., industry surveys) and the collection of in depth essays from each panel member, with experts given carte blanche to prophesize how the industry will look and operate in the future from both an economic and practical perspective.

New panel members:
Vijay Shah, COO at Piramal Enterprises and pharma business lead
Mark Carver, Senior Vice President, Research, Development & Innovation at Fujifilm Diosynth
Sam Venugopal, Director in the Healthcare Practice at PWC
William Botha, Consultant and Founder Interlean
Prabir Basu, former Executive Director at NIPTE
Emil Ciurczak, expert on spectroscopy and PAT
Dilip G Shah, CEO of Vision Consulting Group

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here